Informed consent in breast cancer screening can lead to different choices: 20% of women in their 40s may choose to delay mammograms when presented with comprehensive risk-benefit information.

Pancreatic cystic lesions have a pooled prevalence of up to 8% in the general population, with incidence increasing with age and varying by geographical region.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

Basal cell carcinoma, while common, rarely leads to death when detected and treated early. Physicians should be aware of the seven warning signs that can be mistaken for harmless skin conditions.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

MCED tests aim to detect multiple cancer types through a single blood test, potentially simplifying cancer screening and expanding detection capabilities. However, their implementation raises critical questions about evidence standards and evaluation methods.